Prostate cancer Board decisions

The Board dismissed the claims for service connection for left and right upper and lower extremity peripheral neuropathy, glaucoma, as well as erectile dysfunction, vertigo, syncope, fatigue, hypertension, prostate cancer, and a heart disability due to the grant of service connection in an August 2024 rating decision.

The Board remands the issue of entitlement to service connection for prostate cancer due to inadequate consideration of arguments regarding the adequacy of the DTRA's dose estimate.

The Board granted earlier effective dates for service connection and ratings for various conditions, including diabetes mellitus, neuropathy of the lower extremities, and right wrist limited dorsiflexion.

The Board granted service connection for prostate cancer, resolving reasonable doubt in favor of the Veteran and finding credible evidence that he was exposed to herbicide agents during his service near the Korean DMZ.

The case is remanded for further development, including obtaining updated medical records and providing an addendum opinion.

The Board remands the claim for further development under the PACT Act to confirm the Veteran's participation in a toxic exposure risk activity (TERA) related to potential herbicide agent exposure.

The Board granted an effective date of September 29, 2023 for the grants of service connection for bladder cancer, skin rash due to chemotherapy, residuals of prostate cancer, hypertension and erectile dysfunction.

The Board granted service connection for prostate cancer and erectile dysfunction, with an effective date of March 29, 2012. The claim for an earlier effective date for special monthly compensation based on statutory housebound was denied.

The Board granted the reinstatement of the 100 percent rating for prostate cancer effective October 1, 2024, as the reduction was improper due to an inadequate examination and incomplete record.

The Board found that the reduction in rating for residuals of prostate cancer status post robotic prostatectomy in remission from 100 percent to 20 percent was not in accordance with law and is void ab initio, and the issue of entitlement to a TDIU is dismissed as moot.

The Board dismissed the appeal for service connection for right wrist, hypertension, and prostate cancer due to an improper concurrent election of review options under the Appeals Modernization Act.

The Board remands the Veteran's claim for service connection for prostate cancer to correct pre-decisional duty to assist errors.

The Board denied service connection for ischemic heart disease, prostate cancer and its associated residual symptoms, and diabetic left foot cellulitis and a residual scar as they were not shown in service or for many years thereafter and are not otherwise etiologically related to the Veteran's active duty service.

The Board remands the claim for service connection for prostate cancer, to include residuals, due to a need for additional development of evidence.

The Board denied the veteran's claim for service connection for prostate cancer, finding that the probative evidence does not support a link between the condition and his active service.

The Board remands the claims for service connection for erectile dysfunction and prostate cancer to correct pre-decisional duty-to-assist errors.

The Board denied service connection for a traumatic brain injury, denied earlier effective dates for the grant of service connection for erectile dysfunction and special monthly compensation based on loss of use of a creative organ, and denied an earlier effective date for the award of a 100 percent disability rating for prostate cancer.

The Board granted service connection for tinnitus and hypertension, dismissed the claims for a bilateral hearing loss disability, high cholesterol, and other conditions as moot or denied, and remanded several issues for further development.

The Board denied the veteran's claims for service connection for diabetes mellitus type II, hypertension, hypothyroidism, a heart disorder, and prostate cancer as new and relevant evidence was not received to support readjudication of these claims.

The Board remands the claim for further development of medical opinion evidence regarding the etiology of the Veteran's prostate cancer, specifically addressing its potential connection to exposure to contaminated water at Camp Lejeune.